3D bioprinting is experiencing rapid growth as the technology continues to evolve. This is certainly the case in Australia and AXT, who are already well entrenched in the field are pleased to announce that they are strengthening their position by partnering with CELLINK.
Santhera fully divests rare eye disease drug Raxone to Chiesi – Pharmaceutical Technology
Santhera expects to maximise the reduced financial burden of the Raxone development programme to focus on vamorolone’s European launch. Credit: MIRCO EMMY / Shutterstock. Santhera
July 31, 2023